It has been shown that perhexiline, a small drug that is approved for clinical use in many countries except the United States, to treat angina and heart failure, can effectively induce KLF14 expression in the liver while reducing atherosclerosis in ApoE-null mice (92). This evidence concerns the gene APOE and angina pectoris.